Home / Intelligence / White Papers / Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased implementation of cost-effectiveness policies and the emergence of the consequences of these pricing controls and cost-effectiveness measures, including the Inflation Reduction Act (IRA) and Germany’s Financial Stabilization Act. Regulatory and payer strategies continued to evolve in 2023, and this white paper seeks to illustrate the key consequences of new therapeutic advances and policies aiming to control costs globally and assess their impacts for pharmaceutical manufacturers.
Interested in hearing expert discussion on this white paper?
Register for our
upcoming webinar.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Blog
Rise with the waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future
Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]
Read More
Webinars
2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]
Sign Up Now
White Papers
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Read More